Status:

COMPLETED

Duloxetine for the Treatment of Generalized Anxiety Disorder

Lead Sponsor:

Eli Lilly and Company

Collaborating Sponsors:

Boehringer Ingelheim

Conditions:

Generalized Anxiety Disorder

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This is a 15 week study comparing how well duloxetine and placebo treatments improve generalized anxiety disorder

Eligibility Criteria

Inclusion

  • Psychiatric Diagnosis of generalized anxiety disorder (GAD)
  • Outpatients
  • Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis for GAD
  • Clinical Global Impression (CGI) of Severity Score of at least moderate
  • Sheehan Disability Scale (SDS) Global Functioning Impairment Score \>= 12

Exclusion

  • Pregnancy or breast feeding
  • Serious medical illness
  • Other primary psychiatric diagnoses, such as major depressive disorder or substance abuse disorder within the past 6 months
  • panic disorder, post-traumatic stress disorder (PTSD), or eating disorder in the last year
  • lifetime history of bipolar or psychosis
  • Any unstable serious medical condition for which duloxetine would not be allowed
  • Any use of medications that are not allowed

Key Trial Info

Start Date :

December 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2010

Estimated Enrollment :

210 Patients enrolled

Trial Details

Trial ID

NCT00803361

Start Date

December 1 2008

End Date

January 1 2010

Last Update

December 17 2010

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Beijing, China, 100088

2

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Guangzhou, China, 510370

3

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Hangzhou, China, 310009

4

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Kunming, China, 650032